| Multiple Myeloma
Empliciti vs Xpovio
Side-by-side clinical, coverage, and cost comparison for multiple myeloma.Deep comparison between: Empliciti vs Xpovio with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsXpovio has a higher rate of injection site reactions vs Empliciti based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Xpovio but not Empliciti, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Empliciti
Xpovio
At A Glance
IV infusion
Weekly to every 4 weeks
SLAMF7 antagonist
Oral
Once or twice weekly
XPO1 inhibitor
Indications
- Multiple Myeloma
- Multiple Myeloma
- Diffuse Large B-Cell Lymphoma
Dosing
Multiple Myeloma (with lenalidomide and dexamethasone) 10 mg/kg IV weekly for cycles 1 and 2 (28-day cycles), then 10 mg/kg every 2 weeks until disease progression or unacceptable toxicity.
Multiple Myeloma (with pomalidomide and dexamethasone) 10 mg/kg IV weekly for cycles 1 and 2 (28-day cycles), then 20 mg/kg every 4 weeks until disease progression or unacceptable toxicity.
Multiple Myeloma (with Bortezomib and Dexamethasone) 100 mg orally once weekly on Day 1 of each week in combination with bortezomib 1.3 mg/m2 SC once weekly and dexamethasone 20 mg orally twice weekly on Days 1 and 2.
Multiple Myeloma (with Dexamethasone) 80 mg orally on Days 1 and 3 of each week in combination with dexamethasone 20 mg orally on Days 1 and 3 of each week.
Diffuse Large B-Cell Lymphoma 60 mg orally on Days 1 and 3 of each week until disease progression or unacceptable toxicity.
Contraindications
—
—
Adverse Reactions
Most common (>=10%) Fatigue, diarrhea, pyrexia, constipation, cough, peripheral neuropathy, nasopharyngitis, upper respiratory tract infection, decreased appetite, pneumonia, pain in extremities, headache, vomiting, weight decreased, lymphopenia, cataracts, oropharyngeal pain
Serious Pneumonia, pyrexia, respiratory tract infection, anemia, pulmonary embolism, acute renal failure
Most common (>=20%) Fatigue, nausea, thrombocytopenia, decreased appetite, diarrhea, vomiting, weight decreased, anemia, peripheral neuropathy, upper respiratory tract infection, hyponatremia, cataract
Serious Thrombocytopenia, neutropenia, gastrointestinal toxicity (nausea, vomiting, diarrhea, weight loss), hyponatremia, serious infection (including pneumonia and sepsis), neurological toxicity, cataract
Pharmacology
Elotuzumab is a humanized IgG1 monoclonal antibody that targets SLAMF7 on myeloma cells and natural killer (NK) cells, directly activating NK cells through the SLAMF7 pathway and mediating killing of myeloma cells via antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).
Selinexor reversibly inhibits exportin 1 (XPO1), blocking nuclear export of tumor suppressor proteins and oncogenic mRNAs, causing nuclear accumulation of tumor suppressors, downregulation of oncoproteins such as c-myc and cyclin D1, cell cycle arrest, and apoptosis of cancer cells.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Empliciti
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (0/12)
Xpovio
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Empliciti
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Xpovio
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Empliciti
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Xpovio
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0
Bristol-Myers Squibb Patient Assistance Foundation (BMSPAF)Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$5/momo
Xpovio Co-Pay CardCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
EmplicitiView full Empliciti profile
XpovioView full Xpovio profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.